Indija - angļu - Central Drugs Standard Control Organization

kramer - diethyl carbamazine citrate,chlorpheniramine maleate - tab - 150,2.5;mg - 10

Indija - angļu - Central Drugs Standard Control Organization

kramer - diethyl carbamazine citrate,chlorpheniramine maleate - syr - 100,2.5;mg;5ml - 100ml

Izraēla - angļu - Ministry of Health

truemed ltd, israel - sodium phenylbutyrate - granules - sodium phenylbutyrate 483 mg/g - sodium phenylbutyrate - pheburane is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. it is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy.

Eiropas Savienība - angļu - EMA (European Medicines Agency)

immedica pharma ab - sodium phenylbutyrate - ornithine carbamoyltransferase deficiency disease; citrullinemia; carbamoyl-phosphate synthase i deficiency disease - other alimentary tract and metabolism products, - ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase orargininosuccinate synthetase.it is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease(partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy.

Eiropas Savienība - angļu - EMA (European Medicines Agency)

eurocept international b. v. - sodium phenylbutyrate - carbamoyl-phosphate synthase i deficiency disease - various alimentary tract and metabolism products - treatment of chronic management of urea-cycle disorders.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

orpharma nz limited - sodium phenylbutyrate 84 g equivalent to 483 mg of sodium phenylbutyrate per gram of granules;  ;   - oral granules - 483 mg - active: sodium phenylbutyrate 84 g equivalent to 483 mg of sodium phenylbutyrate per gram of granules     excipient: ethylcellulose hypromellose macrogol 1500 povidone sugar spheres - pheburane is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. pheburane should be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, and protein-free calorie supplements). pheburane is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. geriatrics (> 65 years of age): pheburane has not been studied in the geriatric population.